<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00602706</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000582552</org_study_id>
    <secondary_id>P30CA015083</secondary_id>
    <secondary_id>MC9981</secondary_id>
    <secondary_id>1046-99</secondary_id>
    <nct_id>NCT00602706</nct_id>
  </id_info>
  <brief_title>Samarium Sm 153 Lexidronam Pentasodium and High-Dose Melphalan in Treating Patients With Multiple Myeloma Undergoing Stem Cell Transplant</brief_title>
  <official_title>A Phase I/II Dose Escalation Study Assessing the Toxicity and Efficacy of 153-Samarium-EDTMP in Place of TBI in the Conditioning Regimen for PBSCT for Patients With Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as melphalan, work in different ways to stop the&#xD;
      growth of cancer cells either by killing the cells or by stopping them from dividing.&#xD;
      Samarium Sm 153 lexidronam pentasodium contains a radioactive substance that kill cancer&#xD;
      cells. Peripheral blood stem cell transplant using stem cells from the patient may be able to&#xD;
      replace immune cells that were destroyed by chemotherapy and radioactive drugs used to kill&#xD;
      cancer cells.&#xD;
&#xD;
      PURPOSE: This phase I/II trial is studying the side effects and best dose of samarium Sm 153&#xD;
      lexidronam pentasodium when given together with high-dose melphalan in treating patients with&#xD;
      multiple myeloma undergoing stem cell transplant.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  To find the maximum tolerated dose of samarium Sm 153 lexidronam pentasodium when given&#xD;
           with fixed high-dose melphalan as a conditioning regimen for autologous peripheral blood&#xD;
           stem cell transplantation in patients with multiple myeloma. (Phase I)&#xD;
&#xD;
        -  To assess the response rates of this regimen in these patients. (Phase II)&#xD;
&#xD;
      OUTLINE: This is a phase I, dose-escalation study of samarium Sm 153 lexidronam pentasodium&#xD;
      followed by a phase II study.&#xD;
&#xD;
        -  Phase I: Patients receive samarium Sm 153 lexidronam pentasodium IV once between days&#xD;
           -14 and -10. Patients also receive melphalan IV on day -1. Patients undergo peripheral&#xD;
           blood stem cell transplantation on day 0. Patients receive sargramostim (GM-CSF)&#xD;
           subcutaneously once daily beginning on day 6 and continuing until blood counts recover.&#xD;
&#xD;
        -  Phase II: Patients receive samarium Sm 153 lexidronam pentasodium at the MTD determined&#xD;
           in phase I .&#xD;
&#xD;
      Blood samples are collected periodically to determine clearance of samarium Sm 153 lexidronam&#xD;
      pentasodium and bone marrow dosimetry.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2000</start_date>
  <completion_date type="Actual">July 2010</completion_date>
  <primary_completion_date type="Actual">June 2003</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Number of toxicity incidents (Phase I)</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of successes (Phase II)</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of responses (Phase I)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (Phase II)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (Phase II)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression (Phase II)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progressive disease variables</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">76</enrollment>
  <condition>Multiple Myeloma and Plasma Cell Neoplasm</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>sargramostim</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>melphalan</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>autologous hematopoietic stem cell transplantation</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>peripheral blood stem cell transplantation</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>samarium Sm 153 lexidronam pentasodium</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of multiple myeloma requiring treatment&#xD;
&#xD;
          -  Must have at least 2 x 10^6 CD34+ cells collected for peripheral blood stem cell&#xD;
             transplantation&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Inclusion criteria:&#xD;
&#xD;
          -  ECOG performance status (PS) 0-2 (ECOG PS &gt; 2 allowed if secondary to neuropathy or&#xD;
             acute bone event)&#xD;
&#xD;
          -  Direct bilirubin ≤ 2.0 mg/dL&#xD;
&#xD;
          -  Alkaline phosphatase ≤ 750 μ/L&#xD;
&#xD;
          -  Creatinine ≤ 3.0 mg/dL&#xD;
&#xD;
          -  Ejection fraction ≥ 45%&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception for 6 months after the completion of&#xD;
             study therapy&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  DLCO &lt; 50%&#xD;
&#xD;
          -  FVC &lt; 50%&#xD;
&#xD;
          -  FEV_1 &lt; 50%&#xD;
&#xD;
          -  Active malignancy with the exception of nonmelanoma skin cancer&#xD;
&#xD;
          -  Uncontrolled infection&#xD;
&#xD;
          -  NYHA class III-IV cardiac disease&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  May or may not have received prior chemotherapy&#xD;
&#xD;
          -  At least 3 weeks since prior chemotherapy&#xD;
&#xD;
               -  Cyclophosphamide pulsing for stem cell collection allowed&#xD;
&#xD;
          -  At least 4 weeks since prior biologic therapy&#xD;
&#xD;
          -  At least 2 weeks since prior bisphosphonates and bisphosphonates maybe resumed 1 month&#xD;
             post-study treatment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Angela Dispenzieri, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <verification_date>May 2011</verification_date>
  <study_first_submitted>January 15, 2008</study_first_submitted>
  <study_first_submitted_qc>January 24, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 28, 2008</study_first_posted>
  <last_update_submitted>May 13, 2011</last_update_submitted>
  <last_update_submitted_qc>May 13, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 16, 2011</last_update_posted>
  <responsible_party>
    <name_title>Angela Dispenzieri, M.D.</name_title>
    <organization>Mayo Clinic Cancer Center</organization>
  </responsible_party>
  <keyword>refractory multiple myeloma</keyword>
  <keyword>stage I multiple myeloma</keyword>
  <keyword>stage II multiple myeloma</keyword>
  <keyword>stage III multiple myeloma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Plasmacytoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Samarium Sm-153 lexidronam</mesh_term>
    <mesh_term>Sargramostim</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

